Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: A pilot study

S. Craig Risch; Michael D. Horner; Susan R. McGurk; Simmy Palecko; John S. Markowitz; Ziad Nahas; C. Lindsay DeVane

doi:10.1016/j.schres.2007.01.001

Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: A pilot study

S. Craig Risch, Michael D. Horner, Susan R. McGurk, Simmy Palecko, John S. Markowitz, Ziad Nahas, C. Lindsay DeVane

Psychiatry & Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Thirteen outpatients with chronic but stable schizophrenia received donepezil and placebo augmentation of their maintenance antipsychotic medication regimen. Each subject received in a randomized, counterbalanced order 1) donepezil 5 mg for 6 weeks then donepezil 10 mg for six weeks and 2) placebo donepezil for 12 weeks. Serial ratings of the Positive and Negative Symptom Scale (PANSS) [Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13(2): 261-276] were performed by a trained rater blind to the donepezil order and condition: at baseline, 12 weeks and 24 weeks. On donepezil as compared to baseline or placebo, there was a significant improvement in PANSS negative scores (p = .018, n = 13). These results are discussed with respect to other studies using cholinesterase inhibitors as an augmentation strategy in schizophrenia.

Original language	English (US)
Pages (from-to)	131-135
Number of pages	5
Journal	Schizophrenia Research
Volume	93
Issue number	1-3
DOIs	https://doi.org/10.1016/j.schres.2007.01.001
State	Published - Jul 2007

Bibliographical note

Funding Information:
Dr. Risch is currently or has been in the past on the speakers’ bureau, a consultant, or has received research funds from the following sources: Abbott, Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Novartis, Pfizer, and the NIMH. Dr. McGurk is on the speakers’ bureau for Janssen and Pfizer. Dr. DeVane is on the speakers’ bureau, a consultant, or has received research funding from Theracos, Inc., Novodel Inc., Quintiles Inc., GlaxoSmithKline, Janssen, Eli Lilly, NIDA and NIMH. Dr. Markowitz is currently or has been in the past on the speakers’ bureau, a consultant, or has received research funding from Novartis, Janssen, Eli Lilly, and NICHD. Dr. Nahas is currently or has been in the past on the speakers’ bureau, a consultant, or has received research funds from the following sources: Neuronetics Inc, Cyberonics Inc, Medtronic Inc. Neuropace, Integra, Eli Lilly, Avenir Pharmaceutical, Aventis Pharmaceutical, Astra Zeneca in addition to funding from the NIMH and NARSAD.

Funding Information:
This work was supported, in part, by unrestricted educational grants from Eli Lilly and Company, and from Janssen Pharmaceutical Company.

Keywords

Cholinesterase Inhibitors
Pharmacological Augmentation
Schizophrenia

Access

10.1016/j.schres.2007.01.001

OpenUrl availability

Full text

Cite this

@article{a2a6ed2d0aa143d297f9e4efb406eaf7,

title = "Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: A pilot study",

abstract = "Thirteen outpatients with chronic but stable schizophrenia received donepezil and placebo augmentation of their maintenance antipsychotic medication regimen. Each subject received in a randomized, counterbalanced order 1) donepezil 5 mg for 6 weeks then donepezil 10 mg for six weeks and 2) placebo donepezil for 12 weeks. Serial ratings of the Positive and Negative Symptom Scale (PANSS) [Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13(2): 261-276] were performed by a trained rater blind to the donepezil order and condition: at baseline, 12 weeks and 24 weeks. On donepezil as compared to baseline or placebo, there was a significant improvement in PANSS negative scores (p = .018, n = 13). These results are discussed with respect to other studies using cholinesterase inhibitors as an augmentation strategy in schizophrenia.",

keywords = "Cholinesterase Inhibitors, Pharmacological Augmentation, Schizophrenia",

author = "Risch, {S. Craig} and Horner, {Michael D.} and McGurk, {Susan R.} and Simmy Palecko and Markowitz, {John S.} and Ziad Nahas and DeVane, {C. Lindsay}",

note = "Funding Information: Dr. Risch is currently or has been in the past on the speakers{\textquoteright} bureau, a consultant, or has received research funds from the following sources: Abbott, Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Novartis, Pfizer, and the NIMH. Dr. McGurk is on the speakers{\textquoteright} bureau for Janssen and Pfizer. Dr. DeVane is on the speakers{\textquoteright} bureau, a consultant, or has received research funding from Theracos, Inc., Novodel Inc., Quintiles Inc., GlaxoSmithKline, Janssen, Eli Lilly, NIDA and NIMH. Dr. Markowitz is currently or has been in the past on the speakers{\textquoteright} bureau, a consultant, or has received research funding from Novartis, Janssen, Eli Lilly, and NICHD. Dr. Nahas is currently or has been in the past on the speakers{\textquoteright} bureau, a consultant, or has received research funds from the following sources: Neuronetics Inc, Cyberonics Inc, Medtronic Inc. Neuropace, Integra, Eli Lilly, Avenir Pharmaceutical, Aventis Pharmaceutical, Astra Zeneca in addition to funding from the NIMH and NARSAD. Funding Information: This work was supported, in part, by unrestricted educational grants from Eli Lilly and Company, and from Janssen Pharmaceutical Company. ",

year = "2007",

month = jul,

doi = "10.1016/j.schres.2007.01.001",

language = "English (US)",

volume = "93",

pages = "131--135",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier",

number = "1-3",

}

TY - JOUR

T1 - Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia

T2 - A pilot study

AU - Risch, S. Craig

AU - Horner, Michael D.

AU - McGurk, Susan R.

AU - Palecko, Simmy

AU - Markowitz, John S.

AU - Nahas, Ziad

AU - DeVane, C. Lindsay

N1 - Funding Information: Dr. Risch is currently or has been in the past on the speakers’ bureau, a consultant, or has received research funds from the following sources: Abbott, Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Novartis, Pfizer, and the NIMH. Dr. McGurk is on the speakers’ bureau for Janssen and Pfizer. Dr. DeVane is on the speakers’ bureau, a consultant, or has received research funding from Theracos, Inc., Novodel Inc., Quintiles Inc., GlaxoSmithKline, Janssen, Eli Lilly, NIDA and NIMH. Dr. Markowitz is currently or has been in the past on the speakers’ bureau, a consultant, or has received research funding from Novartis, Janssen, Eli Lilly, and NICHD. Dr. Nahas is currently or has been in the past on the speakers’ bureau, a consultant, or has received research funds from the following sources: Neuronetics Inc, Cyberonics Inc, Medtronic Inc. Neuropace, Integra, Eli Lilly, Avenir Pharmaceutical, Aventis Pharmaceutical, Astra Zeneca in addition to funding from the NIMH and NARSAD. Funding Information: This work was supported, in part, by unrestricted educational grants from Eli Lilly and Company, and from Janssen Pharmaceutical Company.

PY - 2007/7

Y1 - 2007/7

N2 - Thirteen outpatients with chronic but stable schizophrenia received donepezil and placebo augmentation of their maintenance antipsychotic medication regimen. Each subject received in a randomized, counterbalanced order 1) donepezil 5 mg for 6 weeks then donepezil 10 mg for six weeks and 2) placebo donepezil for 12 weeks. Serial ratings of the Positive and Negative Symptom Scale (PANSS) [Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13(2): 261-276] were performed by a trained rater blind to the donepezil order and condition: at baseline, 12 weeks and 24 weeks. On donepezil as compared to baseline or placebo, there was a significant improvement in PANSS negative scores (p = .018, n = 13). These results are discussed with respect to other studies using cholinesterase inhibitors as an augmentation strategy in schizophrenia.

AB - Thirteen outpatients with chronic but stable schizophrenia received donepezil and placebo augmentation of their maintenance antipsychotic medication regimen. Each subject received in a randomized, counterbalanced order 1) donepezil 5 mg for 6 weeks then donepezil 10 mg for six weeks and 2) placebo donepezil for 12 weeks. Serial ratings of the Positive and Negative Symptom Scale (PANSS) [Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13(2): 261-276] were performed by a trained rater blind to the donepezil order and condition: at baseline, 12 weeks and 24 weeks. On donepezil as compared to baseline or placebo, there was a significant improvement in PANSS negative scores (p = .018, n = 13). These results are discussed with respect to other studies using cholinesterase inhibitors as an augmentation strategy in schizophrenia.

KW - Cholinesterase Inhibitors

KW - Pharmacological Augmentation

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=34249317238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249317238&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2007.01.001

DO - 10.1016/j.schres.2007.01.001

M3 - Article

C2 - 17391930

AN - SCOPUS:34249317238

SN - 0920-9964

VL - 93

SP - 131

EP - 135

JO - Schizophrenia Research

JF - Schizophrenia Research

IS - 1-3

ER -

Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: A pilot study

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this